Clinical Trial

The Effect of Face-to-Face and Online Training on Cancer Screening on Women's Knowledge, Attıtude and Shyness

Completed
View on ClinicalTrials.gov →
Summary
Cancer is a large group of diseases that occur due to abnormal cell proliferation in almost all organs of the body. Cancer is the second leading cause of death in the world after cardiovascular diseases. The fact that cancer is a preventable disease reveals the importance of cancer screenings. Cancer screening aims to detect it in the early stages when the chance of treatment is high. Screening programs for breast cancer, cervical cancer and colorectal cancer are recommended by WHO. In order for these screening programs to achieve their goals, people within the scope of screening must participate in screening. However, there are many factors involved in participating in these screening programs. Even though health professionals direct people to screening programs, at this point people's knowledge, attitude and shyness levels affect their participation in screening programs. The research is planned to be experimentally pre-test-post-test, and the data will be collected before and after the training to be given face-to-face and online by the researcher. The results obtained as a result of the study will be taken into consideration by midwives in terms of the effect of the education given on cancer screenings on women's knowledge, attitude and shyness levels.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-19.
Status change: Enrolling by Invitation → Completed 2026-03-26
Trial Details
NCT Number NCT06979960
Lead Sponsor Inonu University
Conditions Being Literate, Not Having Any Cognitive, Visual or Orthopedic Disabilities, Being Between the Ages of 50-65, Having a Smart Phone, The Effect of Education on Cancer Screening on the Knowledge Level of Women, The Effect of Education on Cancer Screening on Women's Attitudes, The Effect of Education on Cancer Screening on Women's Shyness Level
Enrollment 68 participants
Start Date 2024-09-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27